X4 Pharmaceuticals
XFOR
52 hedge funds and large institutions have $40.2M invested in X4 Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 10 closing their positions.
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
2% more funds holding
Funds holding: 51 → 52 (+1)
0.09% less ownership
Funds ownership: 2.17% → 2.08% (-0.09%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
37% less call options, than puts
Call options by funds: $266K | Put options by funds: $421K
53% less capital invested
Capital invested by funds: $85.7M → $40.2M (-$45.5M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.89M |
| 2 |
TLP
Tri Locum Partners
New York
|
+$6.66M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$3.23M |
| 4 |
Axa
Paris,
France
|
+$2.37M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$624K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$4.26M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.97M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.67M |
| 4 |
SCM
Sio Capital Management
New York
|
-$2.23M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.16M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
51
Altium Capital Management
New York
| – | -$4.26M | -26,820 | Closed |
|
|
MIM
52
Monashee Investment Management
Boston,
Massachusetts
| – | -$2.97M | -18,714 | Closed |
|
|
DCM
53
Driehaus Capital Management
Chicago,
Illinois
| – | -$2.67M | -16,858 | Closed |
|
|
E
54
Ergoteles
New York
| – | -$365K | -2,298 | Closed |
|
55
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$243K | -1,530 | Closed |
|
|
HF
56
HRT Financial
New York
| – | -$183K | -1,157 | Closed |
|
|
MWM
57
Minot Wealth Management
Westwood,
Massachusetts
| – | -$90K | -567 | Closed |
|
|
TI
58
Trexquant Investment
Stamford,
Connecticut
| – | -$88K | -554 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$7K | -42 | Closed |
|
|
IA
60
IFP Advisors
Tampa,
Florida
| – | -$5K | -33 | Closed |
|
61
JP Morgan Chase
New York
| – | +$885 | +7 | New |
|
XFOR Hedge Fund Activity: Q4 2021 in Review
52 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2021, worth a combined $40.2M — down 53% from $85.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XFOR positions and 10 closed out — a net gain of 3 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.89M. The largest seller was Altium Capital Management, exiting entirely with an estimated $4.26M sold.
- 52 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2021, up from 51 in Q3 2021.
- Funds reported $40.2M of X4 Pharmaceuticals stock for Q4 2021, down 53% quarter-over-quarter.
- 13 funds opened new X4 Pharmaceuticals positions in Q4 2021 and 10 closed out, a net change of +3 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2021 was Point72 Asset Management, an estimated $6.89M added.
- The largest X4 Pharmaceuticals seller in Q4 2021 was Altium Capital Management, an estimated $4.26M sold.
Based on aggregated 13F filings for Q4 2021.